

**RAPID DOSE THERAPEUTICS INC.**  
**(the “Corporation”)**

**WHISTLEBLOWER POLICY**

**General**

Our Code of Ethics and Business Conduct (the “Code”) requires our directors, officers and employees to observe high standards of business and personal ethics in the conduct of their duties and responsibilities. As employees and representatives of the Corporation, or any of its subsidiaries, we must practice honesty and integrity in fulfilling our responsibilities and comply with all applicable laws and regulations.

**Reporting Responsibility**

It is the responsibility of all directors, officers and employees to comply with the Code and to report suspected violations in accordance with this Whistleblower Policy.

**No Retaliation**

No director, officer or employee who, in good faith, reports a violation of the Code shall suffer harassment, retaliation or adverse employment consequence. An employee who retaliates against someone who has reported a violation in good faith is subject to discipline up to and including termination of employment. This Whistleblower Policy is intended to encourage and enable employees and others to raise serious concerns within the Corporation rather than seeking resolution outside the Corporation.

**Reporting Violations**

The Code addresses the Corporation’s open door policy and suggests that employees share their questions, concerns, suggestions or reports with someone who can address them properly. In most cases, an employee’s supervisor is in the best position to address an area of concern. However, if you are not comfortable speaking with your supervisor or you are not satisfied with your supervisor’s response, you are encouraged to speak with Lino Fera, regarding any Human Resources. Supervisors and managers are required to report suspected violations of the Code to the Corporation’s Audit Committee, who has specific and exclusive responsibility to investigate all reported violations.

For allegations of fraud, securities law, or human rights concerns, or when you are not satisfied or uncomfortable with following the Corporation’s open door policy, individuals should contact the Corporation’s Audit Committee directly, using one of the contact methods below.

### **Audit Committee**

The Corporation's Audit Committee is responsible for investigating and resolving all reports and allegations concerning violations of the Code and, at his discretion, shall advise the President and CEO, the CFO and/or the Audit Committee. The Corporation's Audit Committee has direct access to the Board of Directors and is required to report to the Audit Committee at least annually on such compliance activity. The Corporation's Audit Committee consists of Mr. Kenneth Fox and Mr. Brian Howlett. If you are not comfortable speaking with a member of the Audit Committee, you may send your concern in writing addressed as follows:

Rapid Dose Therapeutics Inc.  
1121 Walkers Line, Unit #3  
Burlington, Ontario, Canada  
L7N 2G4

### **Accounting and Auditing Matters**

The Audit Committee of the Board of Directors shall address all reported concerns or allegations regarding corporate accounting practices, internal controls or auditing. The Audit Committee shall work with the Audit Committee until the matter is resolved.

### **Acting in Good Faith**

Anyone filing a report concerning a suspected violation of the Code must be acting in good faith and have reasonable grounds for believing the information disclosed indicates a violation of the Code. Any allegations that prove not to be substantiated and which prove to have been made maliciously or knowingly to be false will be viewed as a serious disciplinary offense.

### **Confidentiality**

Reports of suspected violations may be submitted on a confidential basis by the complainant, or may be submitted anonymously. Reports of suspected violations will be kept confidential to the extent possible, consistent with the need to conduct an adequate investigation.

### **Handling of Reported Violations**

All reports will be taken seriously. The Audit Committee will notify the sender and acknowledge receipt of the suspected violation within fifteen business days. All reports will be promptly investigated and appropriate corrective action will be taken if warranted by the investigation.